Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Aichi, D5550C00001, Japan

Akita, D5550C00001, Japan

Aomori, D5550C00001, Japan

Chiba, D5550C00001, Japan

Ehime, D5550C00001, Japan

Fukuoka, D5550C00001, Japan

Fukushima, D5550C00001, Japan

Gifu, D5550C00001, Japan

Gunma, D5550C00001, Japan

Hiroshima, D5550C00001, Japan

Hokkaido, D5550C00001, Japan

Hyōgo, D5550C00001, Japan

Ibaraki, D5550C00001, Japan

Ishikawa, D5550C00001, Japan

Kagawa, D5550C00001, Japan

Kagoshima, D5550C00001, Japan

Kanagawa, D5550C00001, Japan

Kochi, D5550C00001, Japan

Kumamoto, D5550C00001, Japan

Kyoto, D5550C00001, Japan

Mie, D5550C00001, Japan

Miyagi, D5550C00001, Japan

Miyazaki, D5550C00001, Japan

Nagano, D5550C00001, Japan

Nagasaki, D5550C00001, Japan

Nara, D5550C00001, Japan

Niigata, D5550C00001, Japan

Numakunai, D5550C00001, Japan

Okayama, D5550C00001, Japan

Okinawa, D5550C00001, Japan

Osaka, D5550C00001, Japan

Ōita, D5550C00001, Japan

Saga, D5550C00001, Japan

Saitama, D5550C00001, Japan

Shiga, D5550C00001, Japan

Shimane, D5550C00001, Japan

Shizuoka, D5550C00001, Japan

Tochigi, D5550C00001, Japan

Tokushima, D5550C00001, Japan

Tokyo, D5550C00001, Japan

Tottori, D5550C00001, Japan

Toyama, D5550C00001, Japan

Wakayama, D5550C00001, Japan

Yamagata, D5550C00001, Japan

Yamaguchi, D5550C00001, Japan

Yamanashi, D5550C00001, Japan